Drugs for Lipid Disorders Flashcards
Bile acid sequestrants (resins)
- effect on LDL
- effect on HDL
- effect on TGs
- big decrease LDL
- slight increase HDL
- minimal effect on TG
most effective drug for increasing HDL
niacin
what patients should avoid niacin
those with:
- hepatic dz
- active peptic ulcer
- DM patients
adverse rxn for statins on muscle
- creatinine kinase activity may increase
- rhabdomyolosis
- myopathy
why should you avoid administration of ezetimibe and bile acid sequestrants (resins)
due to impaired ezetimibe absorption
MOA of PCSK9
antibodies bind to PCSK9 and inhibit LDL receptor metabolism
what do resins treat
pts with primary hypercholesteremia
what would you give a patient with hypertriglyceridemia, dysbetalipoproteinemia, and hypertriglyceridemia that results from treatment with viral protease inhibitors (saquinavir, indinavir, or nelfinavir)
fibrates
MOA of Lomitapide
directly binds to and inhibits microsomal triglyceride transfer protein (MTP) which will prevent the assembly of apo-B containing lipoproteins –> reduction in chylomicrons and VLDL and LDL
what is the effect of niacin on fibrinogen and tissue plasminogen
- fibrinogen levels are reduced
- tissue plasminogen activator levels are increased
adverse rxn with Lomitapide
- inhibits CYP3A4 –> interactions with a number of drugs
- GI symptoms
- increase liver aminotransferase levels
- hepatic fat accumulation
what are the two statins NOT metabolized by CYP450
Pitavastatin
Pravastatin
adverse rxn to Mipomersen
- injection site reactions
- flu like sx
- HA
- elevation of liver enzymes
MOA of ezetimibe
selectively inhibits intestinal absorption of cholesterol and phytosterols
- lowers LDL by 18%
- lowers TG by 6%
- raising HDL by 1.3%
adverse rxn for statins on liver
elevation of serum aminotransferase activity
MOA of niacin
inhibits lipolysis of triglycerides in adipose tissue which reduces circulating free fatty acids
- less VLDL and LDL
- catabolism of HDL decreased
MOA of statins
inhibit HMG-CoA reductase, the rate limiting enzyme in cholesterol synthesis, increases surface LDL receptors which reduces circulating LDL levels
liver adverse rxn from fibrates
increased serum transaminases
most effective drug for lowering LDL
statins
therapeutic uses of ezetimibe
- various causes of elevated cholesterol
- mixed hyperlipidemia
MOA of bile acid sequestrants (resins)
positively charged compounds bind to negatively charged bile acids (cholesterol) and increase bile acid excretion up to tenfold
- enhances LDL clearance and lowers levels